O
SGYP

OrbiMed’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

OrbiMed’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-250,000
Closed -$2.08M – 146
2015
Q2 		$2.08M Buy
+250,000
New +$1.21M 0.02% 127

Other funds holding SGYP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OrbiMed's SGYP Position: Q4 2017 in Review

OrbiMed sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2017, closing a stake of 13,621,443 shares — an estimated $39.5M sold.

OrbiMed first reported a position in SGYP in Q1 2015 and held it in 11 quarters. The position peaked at $111M in Q4 2016. 149 funds tracked by Wall St. Rank hold SGYP as of Q4 2017.

  • OrbiMed reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2017 after selling out during the quarter.
  • OrbiMed sold 13,621,443 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2017, an estimated $39.5M.
  • OrbiMed first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2015 and held it in 11 quarters.
  • OrbiMed's Synergy Pharmaceuticals, Inc Common Stock position peaked at $111M in Q4 2016.
  • 149 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2017.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.